Please login to the form below

Not currently logged in
Email:
Password:

Alexandre Lebeaut

This page shows the latest Alexandre Lebeaut news and features for those working in and with pharma, biotech and healthcare.

Ipsen’s liver cancer treatment clears phase III trial

Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Accelerating innovation. Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach. ... At the sharp end of this challenge is Ipsen’s chief scientific officer and executive VP, research and development, Alexandre

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest appointments

  • Dr Sotirios Stergiopoulos leaves Shire for Ipsen Dr Sotirios Stergiopoulos leaves Shire for Ipsen

    His new role will see him report to Alexandre Lebeaut, executive vice-president R&D and chief scientific officer of Ipsen, who said: “Stergiopoulos has extensive experience in directing global medical

  • Ipsen appoints executive vice president Ipsen appoints executive vice president

    Ipsen appoints executive vice president. Alexandre Lebeaut also set to be chief scientific officer. ... Ipsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Meanwhile, Dr Stergiopoulos (pictured left) has been appointed as senior vice president and head of global medical affairs, reporting to R&D lead Dr Alexandre Lebeaut. ... Dr Lebeaut said: “ Sotirios brings extensive experience in directing global

  • Ipsen’s chief scientific officer steps down Ipsen’s chief scientific officer steps down

    Ipsen’ s chief scientific officer steps down. Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut. ... He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics